Video Games Coming Out In 2021

If you need to know the release dates of the best new games 2021 and beyond has in the pipeline, then you've come to exactly the right place. We've gathered all of the video game release dates for upcoming titles and DLC on PS5, Xbox Series X, PS4, Xbox One, PC, and Switch in this useful reference list, so you don't have to go searching anywhere else. Are you ready to hit the toy tracks at tremendous speeds in Hot Wheels Unleashed?

Or would you prefer to kick off another season on the pitch with FIFA 22? If you said yes to either of those then we have great news, as both are coming out this week. No matter what upcoming games you've got on your wishlist, you'll find them all listed here along with their release formats and the exact date you can start playing them. Video games based on Marvel Comics characters have a nearly 40-year history, and at least two more Marvel-based games are scheduled for release this year. The structure of Marvel game launches has changed considerably as the gaming market evolves.

The days of every comic book film adaptation receiving a tie-in video game are in the past, as are the frequent releases of simple side-scrolling games featuring Marvel characters that were produced during the 16-bit era. More Marvel titles are being released for mobile devices today, with console games taking a more selective approach. He lives with his wife, three dogs, and a likely excessive number of video game consoles. When he is not writing, playing video games, watching movies or television, or reading novels or comic books, he occasionally takes some time to sleep. Derek majored in journalism and worked for a print newspaper before discovering the internet.

He is a fan of science fiction and fantasy, video game and tabletop RPGs, classic Hong Kong action movies, and graphic novels. After being immersed in nerd culture for many years, Derek is now happy to write about the media he enjoys instead of just ranting to his friends. It's been a long road for the next installment in the Rainbow Six series. The shooter was originally scheduled to launch in the holiday 2020 season. At the time, it was titled Rainbow Six Quarantine — a title that quickly became awkward as the pandemic forced the world into lockdown. We wouldn't see the game again until E3 2021, where Ubisoft gave it a grand reveal.

The newly named Rainbow Six Extraction was set to be a big fall release, landing on September 16. Just one month later, Ubisoft shockingly delayed the game to January 2022, pushing it over a year past its original launch window. The 2021 video game release schedule is brimming with potential, and gamers everywhere sit in anticipation of the next groundbreaking title, classic remaster or nostalgic remake. The promise held by this year's roster is brilliant, but it isn't always easy to stay on top of what's happening. To help you make sure you find your next favourite adventure as soon and as easily as possible, here's a list of the most important video game releases for the next few months.

We finally got a release date at E3 2021, and 12 Minutes is set to hit PC and Xbox consoles on August 19. Its time-loop narrative structure and entrancing visuals have made this little indie point-and-click adventure one of the most anticipated games since it was first unveiled back in 2019. In top-down perspective, you play a man who must learn the secret to a terrible series of events that befall him in the tiny span of 12 minutes. Reliving that short time over and over, you've got to help him resolve things, and free him from his temporal prison.

It's weird, it's dark, and it's a game that is shaping up to be a must-play in 2021. Deathloopmight be one of the most-anticipated September video game releases after being pushed back a handful of times. Centered around an assassin stuck in a time loop, this mystery is set to release on PlayStation 5 and PC. In some major video game series, key gameplay elements differ significantly from one entry to another.

"Final Fantasy 10," for example, is a turn-based fantasy RPG, whereas the combat in "Final Fantasy 15" takes place in real-time and people drive cars. In virtually every mainline "Mario" game, meanwhile, Mario can jump and will get bigger after eating a mushroom. Like "Mario," the "Monster Hunter" games continue to reel in massive amounts of players by iterating only in minor ways upon the formula long since established in and gradually improved upon over the course of prior entries.

In the video game industry, 2021 is expected to see the release of many new video games. The numerous delays in software and hardware releases due to the continuation of the COVID-19 pandemic has heavily impacted development schedules, leading to many games being delayed into this year or indefinitely. Additionally, computer and console hardware was impacted by the combined effects of semiconductor shortage (partially from post-COVID-19 effects) and a rising growth of bitcoin mining that strained the supply of critical components. Deathloop takes place within a time loop that keeps repeating unless your assassin lead can take out eight targets - but there's also a rival assassin on the island looking to muck up your plan.

You can even control her and hop into other random online players' games to play spoiler. It has been delayed from its planned May launch, but we say take all thetimeyou need to get this upcoming game absolutely right. Since the very beginning of the year, seemingly no title has been safe from a dreaded delay, as some of the year's biggest games move further down the line or to next year. That's led to a much slimmer release schedule than fans initially expected heading into what was projecting as an exciting year for gaming.

Here's a roundup of all the major video game delays that have happened so far. After nearly 20 years, Metroid fans will finally be able to play a new 2D entry in October with the release ofMetroid Dread -- a game that was long thought to be dead before it was announced during Nintendo's E Direct. Dread is set to be the conclusion of the series' main storyand will see Samus exploring the planet ZDR while trying to escape the terrifying EMMI robots. It will add stealth to the expected and iconic Metroid gameplay as Samus hides from the near-indestructible machines.

Metroid Dread will release alongside two new amiibothe provide potentially game-breaking benefits. After a busy Septemberthat included hits like Deathloop and Tales of Arise, October 2021 is continuing the trend of major fall video game releases. From major remasters to new entries in beloved franchises and beyond, this month is packed with exciting new releases for all major platforms. Existing in the barely explored realms that lie between the visual novel, interactive fiction, and RPGs, Scarlet Hollow is a slow-burn horror adventure set in the backwoods of South Carolina. Arriving in town to attend an estranged aunt's funeral, you slowly find yourself embroiled in a peculiar tale of suspicious locals, family rivalries, and unnerving nighttime creatures.

What's so impressive here isn't just the stunning writing and meticulous illustration by comic creator Abby Howard, but the degree of variety on offer. How you experience so much of the story is based on the special skills you choose at the start—you might be extremely attractive or strong, "mystical" or able to talk to animals. Then there are all the dialogue choices you make, the way you behave to certain people, and decisions you make that determine if certain characters live or die. Two chapters are out now, from a total of seven that will release between now and 2023. Developers Black Tabby Games are showing Inkle (Sorcery!, Heaven's Vault) levels of skill here, with a spooky story that'll pull you deep in. July isn't the busiest month for new video game releases, but there are a couple of big titles heading our way, along with a bunch of smaller indie game that look really interesting.

All the latest gaming news, game reviews and trailers The go-to source for comic book and superhero movie fans. The "Life Is Strange" series has become one of the closest things the video game medium has to a recurring soap opera. While each entry brings new characters and storylines, the games often explore social and cultural dynamics with more than a tinge of melancholy.

"True Colors" looks to continue that as we play the character of Alex Chen, who uses her supernatural abilities — the ability to see into and manipulate others' minds — to try to solve the mystery of what happened to her brother. Built from the ground up for the next generation of gaming, NBA 2K21 for PlayStation 5 is the latest title in the world-renowned, best-selling NBA 2K series and delivers an industry-leading sports video game experience. For fans of the Five Nights at Freddy's series, the road to the upcoming Security Breach has been a long one. The horror game was originally supposed to launch in late 2020, but it was quietly pushed to early 2021.

Four months into the year and we hadn't heard a peep about a release date. Now creator Scott Cawthorn has confirmed that the game is moving to late 2021, putting it a full year out from its original launch window. Cawthorn notes that the game's scale has ballooned during the development process and it requires more time and money to complete. Not even Amazon is immune from the current game delay wave, though that may have less to do with COVID-19 than it does for other games on this list. The company has been trying to break into gaming for quite some time now, with weak results. Its free-to-play multiplayer game Cruciblehad a particularly rocky life span after it was put back into beta and then outright canceled.

Originally scheduled to launch this spring, the game was pushed back to August 31 and then delayed again to September 28. Amazon says the decision was made to ensure the game had a proper endgame when it launched, so it's likely the studio is trying to avoid the same pitfalls games that Marvel's Avengers hit at launch. This isn't the busiest time of year for video game releases, but there are still some fun releases to keep you occupied. Gamers looking for a new party game to enjoy with friends can look forward to Mario Party Superstars, which brings back five maps from the Nintendo 64 era games.

Those who prefer to focus on mini-games choose "Mt. Minigames," a new mode that allows players to experience the game in a new way. Unlike Super Mario Party, all of Superstars' modes will be available to play online at launch, and the game supports button controls rather than relying on the Joy Con. All the latest gaming news, game reviews and trailers A one-stop shop for all things video games. October might be the biggest month for first-person shooters in recent memory, and Far Cry 6 kicks it off with a bang. The exploratory open-ended sandbox series allows players to tackle adventures with a level of freedom that few franchises can. This time, players will be going against the chilling, oppressive dictator Anton Castillo - played by Giancarlo Esposito.

The Far Cry games have become staple shooters for countless fans, and it is likely that Far Cry 6 will be a huge game this fall and holiday season. Technically, fall this year begins on Sept. 22, the autumnal equinox. But since this is the busiest time of year for game releases, as publishers and developers fight for dominance in the run-up to the holidays, it only seems right to begin our list of the biggest games of the season early in the month. August looks to be one of the better summer months for new video game releases, headlined by a number of indie game launches, Ghost of Tsushima Director's Cut, and Civ-like Humankind.

The past few years have seen a variety of approaches to Marvel-licensed games. Telltale Games produced a Guardians of the Galaxy game in their signature branching story style. The Marvel vs Capcom and Marvel Ultimate Alliance franchises received sequels after several years of dormancy. The Spider-Man titles from Insomniac Games received critical acclaim, and Iron Man VR became the first virtual reality Marvel game. The Marvel universe MMORPG Marvel Heroes was shut down, and the live-service titleMarvel's Avengers, from publisher Square Enix, stepped in to fill the gap, supported by extensive expansions like War For Wakanda. A number of Lego games based on Marvel characters have been released as well, offering simple, child-friendly takes on the beloved characters.

This new platformer isn't just a remaster of the previous Lego Star Wars games - it promises hundreds of different characters and different levels throughout. It's being pitched as a brand-new Lego video game unlike any other with fun-filled adventures and plenty of humour too. Central to the game is Alphen's relationship with Shionne (a member of the race who have enslaved Alphen's people), and together they must work to overthrow evil.

Plot-wise, it's fairly standard JRPG territory, although Tales of Arise does touch on some pertinent themes, including the violent effects of colonialism on indigenous peoples. In the gaming medium, trailers can oftentimes be deceptive, but that doesn't mean there isn't cause for excitement about the litany of teasers and information drops surrounding upcoming titles. Here's a rundown of some of the most anticipated video games that are slated to publish throughout the rest of the year.

Gotham Knights was originally scheduled to launch sometime in 2021, but many fans predicted that a delay was inevitable. So it's not surprising that the next big Batman game has been pushed to 2022. Warner Bros. casually announced the game's new launch window with a generic message about giving the game more development time. At this point, it's more shocking when major studio games release on time, rather than when they don't.

While it was originally scheduled for a 2020 launch alongside the Xbox Series X debut, Microsoft delayed Halo Infiniteindefinitely. We now know that the company is planning for a fall 2021 launch, putting it a full year out from its original release plan. Like many games on this list, it's not fully clear if the pandemic has been a key factor in Halo's delay. While companies like Ubisoft have been transparent about the struggles of work from home, others are a bit more tight-lipped about why the schedule shake-ups are happening.

Whatever the case may be, Halo Infinite's delay is the most significant to occur yet. Now, it's set to hit Xbox consoles and PC on December 8, barring any additional delays. The Left 4 Dead spiritual successor was supposed to launch this summer, but it has been delayed to October 12. No specific reason was cited for the move outside of the usual "need more time" note.

The good news is that the multiplayer game will get an open beta this summer. So, fortunately, players will still get a chance to play it around the time the full game was supposed to launch. Even games that are just weeks away from launching aren't safe from potential delays. Just a few weeks before grand strategy game Humankind was supposed to drop, the game was pushed back to August 17. The Civilization-like game's sudden shift sounds a little more standard than that of some of the other titles on this list. Developer Amplitude Studios simply noted that it was taking more time to respond to player feedback from a recent test.

It would take an extra few months to work on features like accessibility, A.I., and pacing. It eventually made that adjusted August 17 release date, getting positive reviews. Originally positioned as one of the big games that would launch alongside next-gen consoles in late 2020, developer People Can Fly quietly pushed it back to February 2. As 2021 got into full gear, the game got delayed once again, this time to April 1.

Before the release, players got a demo on February 25 that covered the first few hours of the full game. They offered a safe way to socialise and an escape from a novel and scary situation. But given how 2021 has gone, with its disappointments and ongoing periods of isolation and constant sense of mortal dread, perhaps video games were never going to be able to save us this time. The fact is that being into video games isn't just about playing; it's about the culture. It's meeting friends at Rezzed or EGX or Insomnia, or cosplaying at MCM, or throwing an E3 press conference party and taking a swig every time someone on stage says "awesome". Without these many moments of interpersonal hype-building, without the global drumroll of fervid anticipation, maybe even Half-Life 3 would have struggled to excite people this winter.

On the indie side, we will get cute feline adventure Mineko's Night Market and the beautiful tidying game Unpacking. People who might have never played such games in a busy year may have time to chance on something unusual in 2021. Coming out right around the time COVID-19 restrictions were starting to wind down, It Takes Two offers a welcome opportunity to spend quality time with a partner or friend from the comfort of your own homes. Living up to its title, the game is a two-player-only experience in which each player takes the side of a couple headed for divorce. That might sound grim — but from that premise, the game spins out a sunny, whimsical puzzle platformer in which both players must work together to advance.

It's a clever metaphor for what two people can do in harmony, and a pleasant way to connect with someone either on your couch or thousands of miles away. Between franchises such as God of War, Gran Turismo, Horizon, Pokemon, and Harry Potter, the PS5, Xbox Series X, Switch, PC, and Stadia have some mammoth titles to host. Here's an extensive look into the biggest games and potential release dates too. "Narita Boy" plays with the Metroidvania genre, crafting an interesting game-within-a-game story that pairs well with the game's retro graphics. Pixels combine with hand-drawn animation for a memorable visual experience that gives "Narita Boy" a distinct feel, recalling the 1980s video game era perfectly. "Narita Boy" even won an award at the Unity Showcase Awards in 2021 for its beautiful 2D visuals.

What Does Average Wholesale Price Mean

In the United States, the average wholesale price is a prescription drug term referring to the average price for medications offered at the wholesale level. The metric was originally intended to convey real pricing information to third-party payers, including government prescription drug programs. Commercial publishers of drug pricing data such as Red Book have published AWP data since at least 1970. The pricing information is "based on data obtained from manufacturers, distributors, and other suppliers." However, despite the data source, published AWPs are generally inflated by 20% relative to actual market prices or wholesale acquisition cost for prescription drugs.

Background Pricing drugs in the California Workers' Compensation System has become more difficult as there are increasingly fewer drugs listed in the Medi-Cal primary fee schedule, which is used as the source for CAWCS drug prices. This presents a challenge of providing timely and accurate CAWCS reimbursement. Methods We evaluated physician-dispensed drugs at the transaction level, reimbursed in the CAWCS. Frequency, reimbursement rate, and total and average paid costs were reported. We matched each claim line in the CAWCS to the corresponding unit price of an alternative price benchmark including average wholesale price, wholesale acquisition cost, direct prices, national average drug acquisition cost, and Federal Upper Limit. Results Average wholesale price provided prices for 99.9% of physician-dispensed drug claims, while Medi-Cal, the current primary physician-dispensed drug benchmark provided prices for a lower percentage (92.7%) of claims.

The CAWCS prices were equivalent to 49% of the average wholesale price, 95.5% of Medi-Cal, 126.7% of the wholesale acquisition cost, 266% of the Federal Upper Limit, 64.4% of direct prices, and 197% of national average drug acquisition cost-estimated prices. Conclusions The CAWCS current Medi-Cal pricing for physician-dispensed drugs is better than all alternatives in terms of price availability, transparency, and budget neutrality, but pricing availability may decrease over time as Medi-Cal moves to managed care. National average drug acquisition cost is the next best alternative, but it requires combinations of pricing benchmarks to maximize its price availability. Prescription drug pricing has moved center stage in a health care industry that is becoming more and more complex. With the inclusion of new groups of stakeholders, more varied incentive systems, greater competition, and more complicated benefit structures, the "true" cost of prescription drugs has grown increasingly elusive.

Drug prices are subject to various types of discounts and rebates, seen and unseen, on both the public and private side. Each drug sold by a manufacturer, therefore, is subject to multiple prices, and little is known publicly about this pricing information. In addition, the issue of drug pricing has implications for other payment systems, such as the Medicare resource-based relative value scale for physician reimbursement and the state Medicaid reimbursement formulas for prescription drugs.

In certain instances where providers or pharmacies believe they are inadequately compensated for administering or dispensing prescription drugs, an inflated average wholesale price is relied upon to make up the difference. From a policy perspective, therefore, the AWP is part of a larger pricing infrastructure that requires examination. The continued debate about the establishment of a comprehensive Medicare prescription drug benefit has only intensified policymakers' focus on drug prices.

There is a lack of a uniform proxy for defining direct medical costs in the US. This potentially important source of variation in modelling and other types of economic studies is often overlooked. The extent to which increased expenditures for an intervention can be offset by reductions in subsequent service costs can be directly related to the choice of cost definitions. To demonstrate how different cost definitions for direct medical costs can impact results and interpretations of a cost-effectiveness analysis. The IMS-CORE Diabetes Model was used to project the lifetime (35-year) cost effectiveness in the US of one pharmacological intervention 'medication A' compared with a second 'medication B' for type 2 diabetes mellitus.

The complications modelled included cardiovascular disease, renal disease, eye disease and neuropathy. Complication costs were obtained from a retrospective database study that extracted anonymous patient-level data from adjudicated medical and pharmaceutical claims. Costs for pharmacy services, outpatient services and inpatient hospitalizations were included. Cost definitions for complications included charged, allowed and paid amounts, and for medications included both wholesale acquisition cost and average wholesale price . The cost-effectiveness results differed according to the particular combination of cost definitions employed.

When the analysis incorporated WAC medication prices with charged amounts for complication costs, the incremental cost-effectiveness ratio for medication A versus medication B was $US6337 per QALY. When AWP prices were used with charged amounts, medication A became a dominant treatment strategy, i.e. lower costs with greater effectiveness than medication B. For both allowed and paid scenarios, there was a difference in the ICER of over $US10,300 per QALY when medication prices were defined by WAC versus AWP. Ratios of medication costs to cardiovascular complication costs ranged from under 0.45 to over 1.7, depending upon the combination of costing definitions. Explicitly addressing the cost-definition issue can help provide meaningful cost-effectiveness data to payers for policy development and management of healthcare expenditures.

It can also help move the pharmacoeconomics and outcomes research fields forward in terms of both methodology and practical application. Federal Medicaid law does not dictate the amount that a state may pay for the drug itself. For brand-name drugs or for generic drugs with fewer than three generic versions the reimbursement is the lower of the pharmacist's usual and customary charge to the general public and the drug's estimated acquisition cost.17 The EAC is a state's estimate of the price generally paid by providers for the drug. Most states pay for drugs at a percentage discount below a drug's published AWP.18 Information compiled by the National Pharmaceutical Council indicates that the reimbursement formulas for state Medicaid agencies range from AWP minus 4 percent in Wyoming to AWP minus 15.1 percent in Michigan.

(See Appendix 1 for a complete list of the state Medicaid reimbursement formulas.) The average is 10.31 percent below AWP, according to the DHHS Office of Inspector General . The core of the plaintiffs' claim is that the published AWPs for the drugs at issue did not reflect the discounts and rebates that the drug manufacturers offered to physician providers. The plaintiffs further alleged that the defendant pharmaceutical companies then "marketed the spread"-that is, advertised the potential windfall to providers-in an attempt to increase the market share of their drugs over the competition. Motivating the plaintiffs' complaints, of course, is the fact that an increase to the AWPs directly resulted in an increase to the payments the plaintiffs were required to make in the form of reimbursement, insurance, or coinsurance. According to the district court's "representative" examples, markups to AWPs were significant and unpredictable, ranging from 27.0% to 1131.7%, depending on the drug and the year. A recent report indicated that the drug industry's published wholesale prices, which serve as the basis for Medicare payments to providers, are significantly higher than the providers' actual acquisition costs.

Physicians are able to obtain Medicare-covered drugs at prices significantly below current Medicare payments. (See Figure 1 for an example of this pricing structure.) In certain instances, drug manufacturers may make even deeper discounts available to providers, in exchange for the providers' willingness to prescribe their drugs over those of their competitors. The result is a wide range of unknown prices being paid for prescription drugs by providers, who are then reimbursed a fixed amount by Medicare, leading to widely varying profit margins for different doctors.

The AWP has often been equated with a "sticker price" or "list price," as those terms are used in the automobile industry. It has become an important prescription drug pricing benchmark for payers throughout the health care industry. Despite its name, however, the AWP is not an accurate reflection of actual market prices for drugs.

As noted, it is a price derived from self-reported manufacturer data for both branded and generic drugs. There are no requirements or conventions that the AWP reflect the price of any actual sale of drugs by a manufacturer, or that it be updated at established intervals. It is not defined in law or regulation, and it fails to account for the deep discounts available to various payers, including certain federal agencies, providers, and large purchasers, such as HMOs. The evidence supported a finding that AstraZeneca unfairly and deceptively published an artificial average wholesale price for Zoladex that gave no indication of the actual, substantial discounts and rebates it was providing in the market.

This conduct by the appellant was contrary to Congress's intent in designing the Medicare program, and it clearly transgressed the expectations of the marketplace. That AstraZeneca also used the scheme to attempt to induce physicians, who stood to profit from the difference between their acquisition cost and the AWP-based reimbursement cost, to prescribe the drug to make a profit rather than based on therapeutic concerns underscores the serious nature of the company's conduct. This is precisely the kind of scheme that Chapter 93A was meant to address, and its use to impose liability here is consistent with the Constitution, with federal and state law, and with the goals, purposes, and design of the Medicare program. Reimbursement options for pharmaceuticals reimbursed under Medicare Part B (physician-dispensed drugs) are changing and the new comprehensive Part D Medicare outpatient drug benefit brings further changes. The Medicare Prescription Drug, Improvement and Modernization Act of replaces traditional policy, of reimbursing Part B drugs at 95% of average wholesale price , with a percentage markup over the manufacturer's average selling price; in 2005 an indirect competitive procurement option will be introduced.

In our view, although AWP-based reimbursement has been fraught with problems in the past, these could be fixed by constraining growth in AWP and periodically adjusting the discount off AWP. With these revisions, an AWP-based rule would preserve incentives for competitive discounting and deliver savings to Medicare. By contrast, basing Medicare reimbursement on a manufacturer's average selling price undermines incentives for discounting and, like any cost-based reimbursement rule, may result in higher prices to both public and private purchasers. Indirect competitive procurement for drugs alone, using specialty pharmacies, pharmacy benefit managers, or prescription drug plans, is unlikely to constrain costs to acceptable levels unless contractors retain flexibility to use standard benefit management tools. Folding Part B and Part D into comprehensive contracting with health plans for full health services is likely to offer the most efficient approach to managing the drug benefit.

Average wholesale price is a term which is generally used with prescription drugs. AWP refers to the average value at which wholesalers sell drugs to physicians, pharmacies, and other customers. AWP is the generally accepted standard measure for calculating the cost of a particular medication. It has become an important prescription drug pricing benchmark for prescription drug pricing and reimbursement throughout the health care industry. AWP is generally 20% greater than the value for which a manufacturer sells their products to distributors and large customers. The reimbursement rates between PBMs and pharmacies are based on different pricing benchmarks and depend on the drug type and the pharmacy's degree of market power.

Manufacturers set a drug's list price and sell drugs to wholesalers at the wholesale acquisition cost . Another benchmark, the average wholesale price , is typically calculated to be 20 percent higher than the WAC. Wholesalers — there are three in the U.S., AmeriSource Bergen, Cardinal Health, and McKesson — pass through the price with a small markup and distribute the drug to pharmacies, which are then reimbursed by public and private payers. Retail pharmacies derive 80 percent of their revenue from private insurers and 15 percent of their revenue from Medicaid.25 Private insurers base reimbursement to pharmacies on the AWP, minus a discount. We then present a theoretical framework for the pricing of branded pharmaceuticals, without and then in the presence of prescription drug insurance, noting factors affecting the relative impacts of drug insurance on prices and on utilization.

With this as background, we summarize major long-term trends in copayments and coinsurance rates for retail and mail order purchases, average percentage discounts off Average Whole Price paid by third party payers to pharmacy benefit managers as well as average dispensing fees, and generic penetration rates. To compare methods of prescription reimbursement in Japan and the United States. Data were obtained through interviews and a search of the pharmacy literature using MEDLINE, International Pharmaceutical Abstracts, the Iowa Drug Information Service, and the Internet.

Search terms were pharmacy, dispensing fee, reimbursement, prescriptions, Japan, United States, and average wholesale price . The reimbursement systems for prescriptions differ widely between Japan and the United States. The reimbursement system in the United States is fairly straightforward and easy to understand; it is generally based on product cost (e.g., AWP minus a percentage) plus a small dispensing fee. Reimbursement formulae have four components, including fees for professional dispensing, drug cost, counseling and administration, and medication supplies and devices.

Additionally, various adjustments to the final amount are made based on dosage form, length of therapy, number of prescriptions dispensed by the pharmacy per month, and when the prescription is filled (e.g., after hours, on Sundays or holidays). In Japan, each pharmacist is limited to filling 40 prescriptions per day, but each "prescription" can involve several medication orders, making it difficult to compare Japanese pharmacists' workloads with those of their counterparts in the United States. In addition, Japanese pharmacists are provided remuneration for providing various cognitive services, such as taking a patient history, counseling a patient, consulting with a physician, and identifying drug-related problems. Japan and the United States have very different methods of reimbursing pharmacists for dispensing prescriptions, each with positive and negative features. After leaving community pharmacy to pursue a career in the pharmaceutical industry, my father's questions about prescription drug pricing continued, but the questions now included why prescription prices seemed to increase as they did, and how manufacturers determined the prices they charged to their customers. During the mid-1980s, other civil servants and federal employees— more specifically, members of Congress and Senators—began asking similar questions.

They also wanted to know why manufacturers were often willing to offer such steep discounts to the US Department of Veterans Affairs on the Federal Supply Schedule and through VA depots, while Medicaid was paying among the highest prices. After all, they reasoned, the federal government is the largest volume purchaser of prescription drugs, so it should get the lowest price—or at least a price as low as the manufacturers' best price offered to other customers. The frequency and magnitude of price increases levied by manufacturers also did not go unnoticed by Congress. As if to provide the answers to these questions, Congress incorporated the Medicaid Drug Rebate Program into the budget to become effective January 1991. For new drugs or new formulations of existing drugs, if drug price information is unavailable pursuant to clause of subparagraph , drug manufacturers and wholesalers shall submit drug price information to the department or a vendor designated by the department for the purposes of establishing the actual acquisition cost. Drug price information shall include, but not be limited to, net unit sales of a drug product sold to retail pharmacies in California divided by the total number of units of the drug sold by the manufacturer or wholesaler in a specified period of time determined by the department.

Business owners set prices for the goods and services they provide based on a variety of factors. For a business to be profitable, revenue from the pricing of all goods and services should be greater than the sum of all costs of the business. In the case of pharmacies, pricing of medications for insured patients is determined by contracts with each PBM and the government. The consolidation of the pharmacy industry may offer convenience for patients through features such as 24-hour availability or the option of picking up from alternate locations.8 Furthermore, chain or mass retail pharmacies may reduce prescription drug costs by leveraging their buying power to negotiate lower prices.

For example, chain pharmacies may purchase their drugs directly from manufacturers, bypassing the wholesaler markup in the distribution chain. These lower pharmacy acquisition prices have the potential to reduce costs for the health care system through lower generic reimbursement under MAC and GER schedules, which should then be passed on to plan sponsors and, ultimately, patients. So, with AWP and WAC both excluded from consideration, a new pricing metric descriptor was necessary to determine the Medicaid rebate, and that price became AMP. The paraphrased definition of AMP in the original version of the statute is "the average price paid to the manufacturer for the drug in the States by wholesalers for drugs distributed to the retail pharmacy class of trade .

Federal Supply Schedule prices are not included in the calculation of AMP." This relatively simple and seemingly straightforward definition of AMP would soon be complicated by the fact that the term "retail pharmacy class of trade" was not defined in the statute or in the manufacturers' Rebate Agreement. The customary prompt pay allowance typically provided to wholesalers and other direct customers was also factored into the calculation, along with any discounts to retail pharmacies . Although patient out-of-pocket costs for drugs vary greatly, patients paid a median of 53% more for these drugs in 2016 than they did in 2010, after adjusting for general inflation. During the same period, median household income rose 8.6%,22 so these out-of-pockets costs have increased relative to income.

Because we used claims to determine out-of-pocket costs, this finding persists despite coupons and patient assistance programs aimed at lowering patient spending. To fully understand Medicaid reimbursement for prescription drugs, it is important to understand the Medicaid Drug Rebate Program and the pricing mechanisms on which it is based. In response to concern about the increasing cost of prescription drugs for Medicaid beneficiaries, the Medicaid Drug Rebate Program was implemented as part of the Omnibus Budget Reconciliation Act of 1990. This program requires drug manufacturers to sign a rebate agreement with the federal government in order to receive payment for outpatient prescription drugs provided to Medicaid beneficiaries. The AWP, or average wholesale price, of prescription drugs was intended to represent the average price at which wholesalers sell drugs to physicians, pharmacies, and other customers.

In practice, it is a figure reported by commercial publishers of drug pricing data, such as First DataBank and Thomson Medical Economics. According to the Red Book, published by Thomson Medical Economics, the pricing information is "based on data obtained from manufacturers, distributors, and other suppliers."2 This pricing information is then sold to government entities, private insurance companies, and other purchasers of prescription drugs. U.S. spending on prescription drugs was $323 billion in 2016, up from $216 billion just 10 years ago, according to the latest government data. Pharmaceuticals' share of total healthcare expenses is also growing rapidly. As pharmacies are seemingly being built on every corner, and inside every grocery and department store, the casual observer might assume that retail pharmacies are profiting from this increase in spending on prescriptions.

But, as every pharmacy owner knows, the profit margin on prescription drug sales is slim, and it continues to narrow due to low reimbursement rates set by private and government third-party payers. The AWP does not reflect the acquisition cost for generic drugs.48PBMs pay pharmacies a negotiated MAC that is proprietary and is also not known to states. The difference between the AWP-based payment and the MAC is referred to as the "spread," or profit of the PBM. Because the components of the spread are often unknown, many states do not know how much profit PBMs retain. In 2003 the federal-state Medicaid program provided prescription drug coverage to more than 50 million people. To determine the price that it will pay for each drug, Medicaid uses the average private sector price.

When Medicaid is a large part of the demand for a drug, this creates an incentive for its maker to increase prices for other health care consumers. Using drug utilization and expenditure data for the top 200 drugs in 1997 and in 2002, we investigate the relationship between the Medicaid market share and the average price of a prescription. Our estimates imply that a 10-percentage-point increase in the MMS is associated with a 7 to 10 percent increase in the average price of a prescription.

In addition, the Medicaid rules increase a firm's incentive to introduce new versions of a drug in order to raise price. We find empirical evidence that firms producing newer drugs with larger sales to Medicaid are more likely to introduce new versions. Taken together, our findings suggest that government procurement rules can alter equilibrium price and product proliferation in the private sector.

Introduction California's Workers' Compensation System Department of Industrial Relations questioned the adequacy of the current Medi-Cal fee-schedule pricing and requested analysis of alternatives that maximize price availability and maintain budget neutrality. Objectives To compare CAWCS pharmacy-dispensed drug prices under alternative fee schedules, and identify combinations of alternative benchmarks that have prices available for the largest percentage of PD drugs and that best reach budget neutrality. Methods Claims transaction-level data (2011–2013) from CAWCS were used to estimate total annual PD pharmaceutical payments. Medi-Cal pricing data was from the Workman's Compensation Insurance System . Average Wholesale Prices , Wholesale Acquisition Costs , Direct Prices , Federal Upper Limit prices, and National Average Drug Acquisition Costs were from Medi-Span.